Premium
Cytomegalovirus appendicitis after hematopoietic stem cell transplantation
Author(s) -
Kothari Atul,
Caradine Kari D.,
Rico Crescencio Juan Carlos,
Sasapu Appalanaidu,
Veeraputhiran Muthu K.,
Jethava Yogesh,
Burgess Mary J.
Publication year - 2017
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12747
Subject(s) - alemtuzumab , medicine , hematopoietic stem cell transplantation , cytomegalovirus , ganciclovir , transplantation , complication , immunology , stem cell , appendicitis , virus , viral disease , human cytomegalovirus , surgery , herpesviridae , biology , genetics
We present the case of a young man with acute lymphoblastic leukemia who developed cytomegalovirus ( CMV ) appendicitis after receiving alemtuzumab for acute refractory graft‐versus‐host disease after allogeneic hematopoietic stem cell transplantation ( HSCT ). CMV appendicitis is a rare complication; and we are reporting the first case to our knowledge of CMV appendicitis following HSCT . Our case highlights the importance of recognition of CMV viral reactivation following the use of alemtuzumab. Using a preemptive strategy of checking CMV PCR , with initiation of early effective treatment on detection of CMV replication, may be appropriate following use of alemtuzumab in hematologic malignancies in patients after HSCT .